# US 5,702,902 A · Methods for the diagnosis of body weight disorders including obesity > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 5,702,902 A - Document ID: US5702902A - Status: Granted - Kind: A - Application number: 08/518,878 - Filed: 1995-08-23 - Granted: 1997-12-30 - Earliest claimed: 1994-08-23 - Assignees: Millennium Pharmaceuticals, Inc. - Inventors: Louis Anthony Tartaglia - Web page: https://patentgrep.com/patent/US5702902A ## CPC - C07K 14/5759: {Products of obesity genes, e.g. leptin, obese (OB), tub, fat} - A01K 2217/05: Animals comprising random inserted nucleic acids (transgenic) - A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) - Y10S 930/12: Growth hormone, growth factor other than t-cell or b-cell growth factor, and growth hormone releasing factor; related peptides - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS ## Abstract The present invention relates to methods and compositions for the treatment of body weight disorders, including, but not limited to, obesity. Specifically, the present invention identifies and describes genes which are differentially expressed in body weight disorder states, relative to their expression in normal, or non-body weight disorder states, and/or in response to manipulations relevant to appetite and/or weight regulation. Further, the present invention identifies and describes genes via the ability of their gene products to interact with gene products involved in body weight disorders and/or appetite and/or body weight regulation. Still further, the present invention provides methods for the identification and therapeutic use of compounds as treatments of body weight disorders. Additionally, the present invention describes methods for the diagnostic evaluation and prognosis of various body weight disorders, and for the identification of subjects exhibiting a predisposition to such conditions. ## Claims ### Claim 1 A method for diagnosing body weight disorders, comprising detecting, in a patient sample, the level of: (a) a C5 (SEQ ID NO.:36) or human C5 (SEQ ID NO.:38) gene transcript; (b) a gene transcript containing a nucleotide sequence present in a cDNA within E. coli clone fahs005a (NRRL Accession No. B-21320); (c) a gene transcript containing a nucleotide sequence which hybridizes under stringent conditions to the complement of the gene transcript of (a) or (b); (d) a gene transcript containing a nucleotide sequence which encodes an amino acid sequence depicted in SEQ ID NO.:37, SEQ ID NO.:56 or SEQ ID NO.:51; (e) a gene transcript containing a nucleotide sequence which encodes an amino acid sequence encoded by a cDNA within E. coli clone fahs005a (NRRL Accession No. B-21320); (f) a gene product containing an amino acid sequence encoded by a C5 (SEQ ID NO.:36) or human C5 (SEQ ID NO.:38) gene transcript; (g) a gene product encoded by a nucleotide sequence present in a cDNA within E. coli clone fahs005a (NRRL Accession No. B-21320); or (h) a gene product containing an amino acid sequence depicted in SEQ ID NO.:37, SEQ ID NO.:56 or SEQ ID NO.:51, so that if a differential level in the patient sample is detected relative to a corresponding non-body weight disorder sample, a body weight disorder is diagnosed. ### Claim 2 (depends on 1) The method of claim 1 in which the level is induced in genetically obese individuals. ### Claim 3 (depends on 1) The method of claim 1 in which the level is repressed in genetically obese individuals. ### Claim 4 (depends on 1) The method of claim 1 in which the level is induced by fasting. ### Claim 5 (depends on 1) The method of claim 1 in which the level is repressed by fasting. ### Claim 6 (depends on 1) The method of claim 1 in which the level is repressed by refeeding of a fasted individual. ### Claim 7 (depends on 1) The method of claim 1 in which the level is induced by refeeding of a fasted individual. ### Claim 8 (depends on 1) The method of claim 1 in which the level is induced in underweight individuals. ### Claim 9 (depends on 1) The method of claim 1 in which the level is repressed in underweight individuals. ### Claim 10 (depends on 1) The method of claim 1 in which the level is induced in overweight individuals. ### Claim 11 (depends on 1) The method of claim 1 in which the level is repressed in overweight individuals.